Full-Time
Software solutions for real-world healthcare data
No salary listed
Senior
Sant Cugat del Vallès, Barcelona, Spain
In Person
Aetion provides software solutions that help life sciences companies, regulators, and purchasers make informed decisions using real-world evidence (RWE). Their platform analyzes real-world data to deliver insights into the effectiveness and safety of medical innovations, enabling clients to generate clinical insights that were previously difficult to obtain. Aetion differentiates itself by offering a combination of software, artificial intelligence for data management, and regulatory services, all aimed at maximizing the return on investment for real-world data. The company's goal is to enhance patient care by facilitating quicker and more informed treatment options.
Company Size
201-500
Company Stage
Series C
Total Funding
$203.6M
Headquarters
New York City, New York
Founded
2012
Help us improve and share your feedback! Did you find this helpful?
Medical, dental, & vision insurance
Free membership to OneMedical
FSA
4% 401(k) match
Commuter benefits for parking & transit
Unlimited PTO
Paid parental leave
Wellness stipend
Company activities
Datavant, a leading health data platform company, today announced that it has signed an agreement to acquire Aetion, a leading real-world evidence (RWE) plat...
Exclusive: Datavant to acquire real-world data specialist Aetion, doubling life sciences team.
Datavant is acquiring Aetion, a competitor in the real-world data sector, as reported exclusively by Endpoints News. This acquisition will lead to Datavant doubling its life sciences team. Further details are expected to be announced by Datavant on Thursday.
Aetion's industry-leading platform integrates advanced analytics, scalable workflows and actionable insights empowering organizations to unlock the full potential of their data and achieve measurable impactNEW YORK, March 31, 2025 /PRNewswire/ -- Aetion , the global leader in real-world evidence (RWE) technology and analytics, today announced the availability of its Aetion® Evidence Platform (AEP) in Amazon Web Services (AWS) Marketplace, a digital catalog with thousands of software listings from independent software vendors that make it easy to find, test, buy, and deploy software that runs on AWS. This launch removes implementation barriers, simplifies procurement and enables life sciences organizations, payers and regulators to harness scalable, cloud-based evidence generation with the security and reliability of AWS.AEP empowers organizations to analyze real-world data (RWD) to generate transparent, reproducible and regulatory-grade evidence for decision-making in drug development, market access, policy and pricing. By leveraging AWS Marketplace, Aetion streamlines access to its platform and reliable, fit-for-purpose solutions tailored to meet each organization's specific objectives, as well as accelerating time-to-insights and ensuring compliance with global regulatory standards.Aetion relies on AWS as its core infrastructure, leveraging services such as Amazon Bedrock to power its artificial intelligence and machine learning (AI/ML)-driven capabilities in order to unlock hidden insights about patient populations and translate scientific intent to results. These technologies enhance AEP's ability to process complex RWD at scale, enabling sophisticated hypothesis generation and analysis automation for evidence generation."The availability of AEP in AWS Marketplace underscores our commitment to providing scalable, high-impact solutions that help organizations make real-world data work for them," said Jay Podence, senior vice president of Commercial Partnerships at Aetion. "By integrating with AWS, we offer our new and existing customers a seamless path to deploy and scale real-world evidence studies with enhanced efficiency and security. This is the first step in our vision to expand our collaboration with AWS to bring more value to our customers
NEC's CVC fund, NEC Orchestrating Future Fund, has invested in Aetion, Inc., a U.S. company providing a medical data analysis platform. This investment aims to enhance collaboration in utilizing real-world data (RWD) and real-world evidence (RWE) for drug development. Aetion's platform, Aetion Evidence Platform, is used globally by pharmaceutical companies and healthcare organizations to improve decision-making. NEC and Aetion will explore synergies to streamline drug development processes.